Novel Therapies in Acute Myeloid Leukemia.

OBJECTIVE: To provide a comprehensive review of evidence-based data on the newly approved therapeutic agents in acute myeloid leukemia (AML) with regards to appropriate indications for use, efficacy, and safety.

DATA SOURCES: Published clinical trials and observational studies.

CONCLUSION: Optimal treatment decisions for AML should be personalized based on individual patients' performance status, disease risk as determined by mutational profile, response status, and prior therapies received. While the treatment options have expanded, several questions remain regarding appropriate patient selection, long-term efficacy and safety of these agents, and sequencing of therapies among available options.

IMPLICATIONS FOR NURSING PRACTICE: Nurses need to be familiar with the peculiarities of the administration regimens of newer AML therapies, adopt formal monitoring strategies for side effects that are unique to these agents, and develop a framework to facilitate timeliness of follow-up and monitoring while on these therapies.